Tag: U.S. Biopharma Imports

On May 11, President Donald Trump stunned the pharmaceutical and investment world by announcing he will sign what he describes as “one of the most consequential Executive Orders in our country’s history.” The order, set to be signed at 9:00 A.M. on May 12 at the White House, will mandate that prescription drug prices in…

Over the past decade, U.S. biopharmaceutical imports have surged, crossing $202 billion in 2023 — doubling in just ten years. Despite America’s powerhouse pharmaceutical sector, the country now runs a $101 billion trade deficit in biopharma, as it increasingly relies on imported raw materials, active pharmaceutical ingredients (APIs), and finished drugs, particularly from China, India,…